Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • New therapies for relapsed or...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
New therapies for relapsed or refractory aggressive B‐cell lymphoma increase survival: Analysis from the RELINF registry of the GELTAMO group

New therapies for relapsed or refractory aggressive B‐cell lymphoma increase survival: Analysis from the RELINF registry of the GELTAMO group

Bibliographic Details
Main Authors: Mariana Bastos‐Oreiro, Pau Abrisqueta, Antonio Gutierrez, Ana Jiménez Ubieto, Maria Poza, Paula Fernanez‐Caldas, María José LLacer, Sonia Gonzalez de Villambrosia, Raúl Córdoba, Alberto López, Elena Ceballos, Belen Navarro, Ana Muntañola, Eva Donato, Eva Diez‐Baeza, Lourdes Escoda, Hugo Luzardo, María José Peñarrubia, Daniel García Belmonte, Emilia Pardal, Claudia Lozada, Alejandro Martín García‐Sancho
Format: Article
Language:English
Published: Wiley 2024-04-01
Series:HemaSphere
Online Access:https://doi.org/10.1002/hem3.70
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

https://doi.org/10.1002/hem3.70

Similar Items

  • Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups
    by: Mariana Bastos-Oreiro, et al.
    Published: (2022-07-01)
  • Chimeric antigen receptor T‐cell therapy outcomes in T cell/histiocyte‐rich large B‐cell lymphoma and subsequent treatment strategies after disease progression: A GELTAMO/GETH study
    by: Mariana Bastos‐Oreiro, et al.
    Published: (2025-02-01)
  • PB2329: ENTEROPATHY-ASSOCIATED T-CELL LYMPHOMA (EATL): MULTICENTRIC REVIEW OF CLINICAL FEATURES AND TREATMENT: ON BEHALF OF GELTAMO (GRUPO ESPAÑOL DE LINFOMAS Y TRASPLANTES DE MÉDULA ÓSEA)
    by: Maria Stefania Infante, et al.
    Published: (2023-08-01)
  • Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study
    by: Alejandro Martín García-Sancho, et al.
    Published: (2022-03-01)
  • R‐COMP versus R‐CHOP as first‐line therapy for diffuse large B‐cell lymphoma in patients ≥60 years: Results of a randomized phase 2 study from the Spanish GELTAMO group
    by: Juan‐Manuel Sancho, et al.
    Published: (2021-02-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs